Overview

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Status:
Recruiting
Trial end date:
2021-04-02
Target enrollment:
Participant gender:
Summary
Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Hemay Pharmaceutical Co.,Ltd